Active Biotech AB Interim report January – June 2012
during third quarter 2012
– a Phase III study will be initiated in the US
* TASQ – milestone payment of EUR 10 M received from Ipsen in connection with meeting patient enrolment target
for Phase III study
– overall survival data from Phase II study presented
* ANYARA – Phase III trial continuing according to plan
* 57-57 – a clinical trial in systemic sclerosis/scleroderma in progress
* ISI – project proceeding as planned
* The organization has been adapted to the company’s new direction
* Net sales: SEK 96.6 M (228.8)
* Operating loss: SEK 120.6 M (profit: 70.6)
* Loss after tax: SEK 123.5 M (profit: 77.7)
* Loss per share for the period: SEK 1.79 (earnings: 1.14)
For further information, please contact:
Tomas Leanderson
President and CEO
Tel: +46 (0)46 19 20 95
Hans Kolam
CFO
Tel: +46 (0)46 19 20 44
Active Biotech AB (Corp. Reg. No. 556223-9227)
PO Box 724, SE-220 07 Lund
Tel: +46 (0)46 19 20 00
This report is also available at www.activebiotech.com Fax: +46 (0)46 19 11 00
Active Biotech AB Interim report Jan – June 2012
—
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: Active Biotech via Thomson Reuters ONE
HUG#1633117